Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals is raising equity capital by offering 7,620,000 shares of common stock at $45.95 per share. The gross proceeds are $350,139,000, with underwriting discounts and commissions of $19,257,645, resulting in estimated net proceeds of about $330.2 million, or $379.8 million if underwriters fully exercise their 1,143,000-share option. The company plans to use the cash, together with existing funds, to support the commercial launch of PALSONIFY, advance research and development across its endocrine-focused pipeline, and for general corporate purposes, including possible future in-licensing or acquisitions.
As of September 30, 2025, Crinetics had 94,548,323 shares outstanding. The company reports preliminary, unaudited net product revenue from PALSONIFY of more than $5.0 million for the quarter ended December 31, 2025 and estimates it held approximately $1.0 billion in cash, cash equivalents and investment securities as of that date. Based on the $45.95 offering price, new investors face immediate dilution of $32.22 per share, as net tangible book value is expected to rise from $11.34 to $13.73 per share after the offering.
Crinetics Pharmaceuticals, Inc. reported that Dana Pizzuti, M.D. will step down as Chief Medical and Development Officer effective December 31, 2025. Under a Transition and Separation Agreement, she will serve as a Strategic Regulatory and Development Advisor from January 1, 2026 through up to March 31, 2026. She will receive $577,000 in cash severance, eligibility for a 2025 annual bonus and a prorated 2026 bonus, up to $15,000 of legal fee reimbursement, up to 12 months of COBRA premium reimbursements, and up to $6,500 for a board training course.
Crinetics and Dr. Pizzuti also entered into an Advisor Agreement under which she will provide 10–20 hours per month of services from April 1, 2026 through up to March 30, 2028 for $600 per hour plus expense reimbursement. Certain existing equity awards will continue to vest during this advisory period, with additional vesting protections upon a Change in Control if specified conditions are met. Vested stock options may remain exercisable for up to three years after advisory service ends, subject to a ten-year maximum term.
Crinetics Pharmaceuticals (CRNX) reported Q3 2025 results and its first FDA approval. The FDA approved PALSONIFY (paltusotine) on September 25, 2025 for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. The quarter did not include product sales.
Revenue was $143 thousand, primarily from a Japan license. Operating expenses rose with commercialization and pipeline spend: research and development $90.5 million and selling, general and administrative $52.3 million. Net loss was $130.1 million (basic and diluted loss per share $1.38), compared with a $76.8 million loss a year ago. Other income was $12.5 million, reflecting interest on investments.
Cash, cash equivalents and investment securities totaled $1.09 billion as of September 30, 2025, and management believes this is sufficient for at least 12 months. The company advanced atumelnant in CAH and ADCS and prepared an SST2-targeted NDC (CRN09682) Phase 1/2 start. Shares outstanding were 94,891,840 as of October 28, 2025.
Crinetics Pharmaceuticals submitted a current report to note that it has released financial results for the period ended September 30, 2025. The company issued a press release on November 6, 2025 summarizing its operations and financial condition for that period, and that release is included as an exhibit to this report. The company also clarifies that the information in this report and the attached press release is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions.
Crinetics Pharmaceuticals (CRNX) reported an insider transaction by its Chief Medical and Development Officer. On November 3, 2025, the officer exercised 5,000 stock options at an exercise price of $16.89 per share and, on the same date, sold 4,900 shares at a volume‑weighted average price of $42.65 (price range $42.14–$43.09) and 100 shares at $43.27.
The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025. Following the transactions, the officer directly beneficially owned 66,270 shares of common stock. Derivative securities beneficially owned following the transactions were 74,042 stock options. The option grant vests 25% on September 30, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment.
Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.
Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) shows a proposed sale related to an insider option exercise and subsequent planned sale. The filer reports acquisition of 5,000 common shares on 10/01/2025 via exercise of stock options and indicates an intended sale of those 5,000 shares on 10/01/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $208,250.00. The filing lists 94,175,994 shares outstanding. Recent disclosed 10b5-1 sales by the same person, Dana Pizzuti, include sales on 09/02/2025 (5,000 shares, $160,515), 08/22/2025 (30,000 shares, $912,999), and 08/20/2025 (6,492 shares, $189,426.82). The form includes the standard representation that the seller does not possess undisclosed material adverse information and references reliance on a Rule 10b5-1 plan where applicable.
Crinetics Pharmaceuticals insider sale by President & CEO Richard S. Struthers. The filing reports that on 09/26/2025 Mr. Struthers sold 4,000 shares of common stock in open-market transactions at $45.00 per share under a Rule 10b5-1 trading plan adopted August 30, 2024. The Form 4 lists his post-transaction beneficial holdings across direct and indirect holdings, including 320,017 shares held directly and multiple indirect holdings via family trusts and spouse (for example, 661,205 shares by Family Trust 1 and 106,000 shares indirect by Family Trust 2). The sale was effected automatically under the trading plan and was signed by an attorney-in-fact on 09/30/2025.
Crinetics Pharmaceuticals director Matthew K. Fust reported transactions on 09/26/2025. He exercised 10,000 stock options with a $1.91 exercise price and acquired 10,000 shares, and sold 16,000 shares in open-market transactions at $44.75 per share executed under a Rule 10b5-1 trading plan. After these transactions he beneficially owned 22,836 shares of common stock and held 10,000 stock options (with 2,092 derivative securities reported as beneficially owned following the transactions). The 10,000 options became exercisable per the stated vesting schedule; 1/3 vested on 02/16/2019 with monthly vesting thereafter.
Crinetics Pharmaceuticals (CRNX) filed a Form 144 notifying a proposed sale of 16,000 common shares through Morgan Stanley Smith Barney LLC on 09/26/2025 with an aggregate market value of $574,240.00. The filing shows the shares were acquired as 10,000 via exercise of stock options on 09/26/2025 (paid in cash) and 6,000 as restricted stock units on 06/07/2024. The company reports 94,175,994 shares outstanding and discloses no securities sold by the reporting person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information.